Author:
Fujitani Katsumi,Yamada Takeshi,Makimura Koichi,Mano Yoko,Furuya Nobuhiko
Reference27 articles.
1. Asano, S., et al. (2018). Intellectual property in the field of regenerative medicine in Japan. Clinical Therapeutics, 40(11), 1823–1826.
2. Chesbrough, H. W., & Appleyard, M. M. (2007). Open innovation and strategy. California Management Review, 50(1), 57. FALL.
3. Developmental Therapeutics Program. (n.d.).
https://dtp.cancer.gov/default.htm2020.07
4. Favre, B., & Ryder, N. S. (1996). Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrobial Agents and Chemotherapy, 40, 443–447.
5. Fukushima, M. (2016). The history and forecast of “Project for Translational and Clinical Research Core Centers” The ARO establishment for driving innovation mechanism, and aiming for disruptive innovation. Rinsho Hyoka (Clinical Evaluation), 44(3), 417–428.